Avid Radiopharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Avid Radiopharmaceuticals Inc. has two radiolabeled compounds in clinical trials that specifically and sensitively bind amyloid beta. The company intends to make these products available to pharmaceutical companies that are developing anti-amyloid therapeutics for Alzheimer's disease. Avid's own first commercial product for AD is still in preclinical development and will be visualized using positron emission computed tomography.